After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.
Tampa, Florida-based Biovest has been meeting with regulatory officials to make sure it has the clinical data necessary to win...
Welcome to Scrip
Create an account to read this article
Already a subscriber?